Six readers
| reader | found | score |
|---|---|---|
| genetics Open Targets | no genetic evidence; overall 0.10 from other evidence | 0.00 |
| cell type Human Protein Atlas | cell type enhanced outside the brain (hepatocytes) | 0.10 |
| chemistry Open Targets | a small-molecule pocket | 0.60 |
| trials ClinicalTrials.gov | no Parkinson's trials on record: an open field | 1.00 |
| literature PubMed | 30 Parkinson's papers of 2,104 | 0.55 |
| pathways Reactome | 2 pathways; mostly other | 0.30 |
No case: the score is under the bar. Receipt 2756
Sealed predictions
- NAT2 in dopamine neurons, braak+0.27 (p 0.476) → -0.52 (p 0.148)receipt 2762
Swarm cases
receipt 2762: NAT2 in dopamine neurons, braak
- power
- full sample -0.00 (p 0.997, n 18), 95% CI -0.47 to +0.47. the interval is wide: not enough donors to tell.
- confounder
- adjusted for sex: +0.01 (p 0.969, n 18). does not hold up.
- composition
- dopamine neurons share of nuclei vs axis +0.05 (p 0.854); controlling for it: +0.01 (p 0.983, n 18). could be the mix.
- skeptic
- leave-one-out range -0.12 to +0.12, sign flips 9; without severely affected donors -0.00 (p 0.997, n 18). fragile.
- cell type
- no other cell group does better.
- axis
- no measure beats "tracks Braak Lewy-body stage" for NAT2 in dopamine neurons.
case closed: nothing better to follow up.
Receipts
loading the receipts